Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Omkar Pharmachem's Revenue for the
three
months ended in Jun. 2026 was ₹0.00 Mil. Omkar Pharmachem's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹0.32 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Omkar Pharmachem Receivables Turnover Related Terms
Omkar Pharmachem Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Omkar Pharmachem's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532167 vs CTAS, CPRT, GPN: Receivables Turnover Comparison
For the Specialty Business Services subindustry, Omkar Pharmachem's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omkar Pharmachem Receivables Turnover vs Business Services Industry
For the Business Services industry and Industrials sector, Omkar Pharmachem's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Omkar Pharmachem's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omkar Pharmachem (BOM:532167) has a Receivables Turnover of 0.00 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Omkar Pharmachem and its competitors. According to the industry distribution chart, Omkar Pharmachem ranks #999999 out of 1061 companies in the Business Services industry.
Is Omkar Pharmachem's Receivables Turnover too high?
Omkar Pharmachem's current Receivables Turnover is 0.00. Based on the distribution chart, Omkar Pharmachem ranks #999999 out of 1061 companies in the Business Services industry, which is in the bottom quartile relative to peers. Overall, Omkar Pharmachem has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Omkar Pharmachem's Receivables Turnover compare to CTAS and CPRT?
According to the Business Services industry distribution chart, Omkar Pharmachem ranks #999999 out of 1061 companies for Receivables Turnover. This places Omkar Pharmachem in the lower half of its industry. The industry median Receivables Turnover is 6.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Business Services company?
The median Receivables Turnover among Business Services companies is 6.42, based on 1,061 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Omkar Pharmachem and its competitors. For the Business Services industry, the median Receivables Turnover is 6.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omkar Pharmachem's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omkar Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Omkar Pharmachem (BOM:532167) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹23.90, compared to a current price of ₹9.74 — trading 59.2% below its estimated fair value. The current Receivables Turnover is 0.00. Omkar Pharmachem's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Omkar Pharmachem (BOM:532167), the current Receivables Turnover is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omkar Pharmachem (BOM:532167) Overvalued in 2026?
Based on GuruFocus' analysis, Omkar Pharmachem stock appears to be undervalued.
The current stock price of ₹9.74 is trading 59.2% below its estimated GF Value™ of ₹23.90.
GuruFocus considers Omkar Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:532167:
Receivables Turnover: 0.00
GF Value™: ₹23.90 vs. price of ₹9.74 (59.2% below fair value)
No single metric tells the full story. See the BOM:532167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532167 has been successfully added to your 
